The study tracked the effectiveness of the 2024–2025 season of the COVID-19 vaccine in US veterans using electronic medical records from the Office of Veterans Affairs.[1] It included 164,132 veterans who received both the COVID-19 and flu vaccine on the same day and a comparison group of 131,839 veterans who received only the flu vaccine between September 3 and December 31, 2024.[1] After 6 months of follow-up, the vaccine had an estimated efficacy of 29.3% (95% CI: 19.1–39.2) against emergency room visits related to COVID-19, with a risk difference of 18.3 per 10,000 persons.[1] Efficacy against hospitalizations was 39.2%, against deaths 64%, and against a combination of these outcomes 28.3% (95% CI: 18.2–38.2), with a risk difference of 18.2 per 10,000 persons.[1][3] The vaccine reduced the risk of serious outcomes in all predefined subgroups by age (less than 65 years, 65–75 years, over 75 years), presence of serious comorbidities, and immune status.[1] The absolute risk reduction was small: 18.3 emergency room visits, 7.5 hospitalizations, and 2.2 deaths per 10,000 vaccinees.[3] The study confirms a reduction in the risk of serious clinical outcomes related to COVID-19 after vaccination.[1]